ABSTRACT A randomised, double blind, placebo controlled trial of nedocromil sodium was undertaken to assess its corticosteroid sparing effect in 50 adults with asthma who had required an oral corticosteroid dose of (or equivalent to) at least 5 mg prednisolone a day continuously during the preceding year, in addition to inhaled beclomethasone dipropionate and bronchodilators. Patients having corticosteroids other than prednisolone were changed to prednisolone. A four week baseline period was followed by 20 weeks of inhaled nedocromil sodium (16 mg daily) or placebo. After four weeks of the treatment phase an attempt was made to reduce the oral prednisolone maintenance dose by 2 5 mg a fortnight until a dose of 5 mg daily was reached and thereafter by mg a fortnight, provided that there was no significant clinical deterioration as judged by clinic assessments and daily diary cards. Of 50 patients recruited, 47 entered the treatment phase (age range 16-64 years), 24 receiving nedocromil sodium and 23 placebo. The total steroid reduction achieved was 2 5 mg in the nedocromil group and 3 mg in the placebo group, which did not differ significantly. There was no significant change in symptoms, lung function or inhaler use in either group during the study. The number of patients requiring short term upward adjustment of booster doses of oral prednisolone for exacerbations of asthma was similar in the two groups (26 with placebo, 28 with nedocromil). Thus nedocromil sodium does not appear to provide an oral corticosteroid sparing effect in chronic steroid dependent asthma.
Introduction
Nedocromil sodium is a pyranoquinoline dicarboxylic acid derivative that possesses non-bronchodilator anti-asthma properties,-'10 some of which were reported in the proceedings of a congress on airway inflammation.' Pretreatment with nedocromil sodium has been shown to inhibit the bronchoconstrictor effects of exercise,'13 sulphur dioxide,4 cold air,5 6 and the immediate and late response to allergen provocation.' It has also been shown to attenuate the increase in histamine airway responsiveness during the grass pollen season in pollen sensitive subjects.8 A clinical trial in nonsteroid dependent asthmatic patients showed improved control of asthma.9 We have studied the steroid sparing effects of nedocromil in patients requiring oral corticosteroids in addition to beclomethasone dipropionate. The study had a randomised, double blind, placebo controlled design with an active treatment phase of 20 weeks; the patients had severe asthma requiring oral corticosteroids in a minimum dose of 5 mg prednisolone or its equivalent daily over the last year.
Methods

PATIENTS
Fifty patients with asthma were recruited from the respiratory outpatient clinic at Groote Schuur Hospital (table 1). All patients were aged at least 14 years and had been taking oral prednisolone or an equivalent corticosteroid at a regular daily or alternate day dose averaging at least 5 mg/day for at least one year in addition to regular aerosol and oral Patients were instructed to inhale regular doses of beta2 adrenergic stimulants, with additional doses as considered necessary to control their asthma. The doses of inhaled steroid (beclomethasone dipropionate) and oral bronchodilators were kept constant throughout the study. Those having alternative forms of corticosteroids changed to an equivalent dose of prednisolone. Antibiotics could be used to treat intercurrent infection. Patients completed daily diary cards with details ofasthma severity score, use ofthe test and other medications, and the results of peak expiratory flow readings. The following symptoms were recorded and scored on a five point scale: (a) daytime symptoms (0 indicating no symptoms, I occasional wheeze or breathlessness quickly relieved by bronchodilator aerosol, and 4 severe symptoms resulting in inability to work or engage in usual activities); (b) morning tightness (1 indicating slight tightness and 4 earlier awakening than normal owing to wheeze or cough, necessitating use of bronchodilator aerosol more than once between waking and measurement of morning PEF); (c) nocturnal symptoms (1 indicating awakening on one occasion in the night because of wheezing or cough for less than one hour not necessitating use of a bronchodilator aerosol and 4 being awake most of the night because of wheezing and cough). The best of 983 984 three PEF measurements were recorded three times daily.
At the end ofa four week run in period patients were allocated on the basis of a randomised coding sheet to receive double blind either nedocromil sodium (2 mg per actuation) or placebo delivered by metered dose aerosol at a dose of two actuations four times daily.
After four weeks of treatment, repeated attempts were made to reduce the patients' maintenance dose of oral prednisolone. In those having more than 5 mg the daily dose was reduced by 2 5 mg at each fortnightly visit.Those having 5 mg or less reduced their daily dose by 1 mg at each visit.
Patients attended at two weekly intervals on 10 occasions (total treatment period 20 weeks), and at each visit the severity of asthma, presence of unusual symptoms, and pulmonary function were recorded.
Lung function tests were performed by experienced technicians using the same spirometer (Vitalograph) for FEV, and FVC and peak flow meter (Wright's) for PEF. Inhaled bronchodilator treatment was withheld for four hours before the lung function tests. When this was not possible the lung function record for that visit was excluded from the analysis.
ACUTE ASTHMA ATTACKS
Patients whose asthma deteriorated during the double blind period, to the extent that parenteral corticosteroid or theophylline was needed or admission to hospital was required, were considered to be treatment failures and were withdrawn. When, however, the attack was associated with pyrexia and cough productive of purulent sputum it was considered to be infective rather than a treatment failure; when symptoms subsided the steroid was reduced over two weeks to the dose preceding the infection and further systematic weaning was then attempted according to the study protocol. In most instances the decision to give parenteral treatment was made by doctors in the emergency service of the hospital rather than by the investigators but it was always given when PEF fell and remained below 50% of predicted values, and when nebulisation of fenoterol (I mg in 4 ml normal saline) failed to achieve a sustained response. (fig 3) . The mean steroid reduction in the nedocromil and placebo groups (2 5 Does nedocromil sodium have a steroid sparing effect in adult asthmatic patients? 
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